The estimated Net Worth of Johan Wedell Wedellsborg is at least $80.1 Milion dollars as of 11 December 2023. Mr. Wedellsborg owns over 6,455 units of Y-Mabs Therapeutics Inc stock worth over $60,501,022 and over the last 5 years he sold YMAB stock worth over $19,415,943. In addition, he makes $228,025 as Independent Director at Y-Mabs Therapeutics Inc.
Johan has made over 15 trades of the Y-Mabs Therapeutics Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he bought 6,455 units of YMAB stock worth $44,217 on 11 December 2023.
The largest trade he's ever made was selling 168,244 units of Y-Mabs Therapeutics Inc stock on 20 August 2019 worth over $4,638,487. On average, Johan trades about 41,907 units every 66 days since 2019. As of 11 December 2023 he still owns at least 4,559,233 units of Y-Mabs Therapeutics Inc stock.
You can see the complete history of Mr. Wedellsborg stock trades at the bottom of the page.
Johan Wedell-Wedellsborg is the Independent Director of the Company, Mr. Wedell-Wedellsborg has been the owner and Chairman of the board of Weco A/S ("Weco") since May 2001. Weco is involved in shipping, investments in biotechnology companies, real estate investments and the financial services industry. Mr. Wedell-Wedellsborg is the majority owner of WG Biotech ApS, one of our principal stockholders. Mr. Wedell-Wedellsborg currently serves as a member of our Audit Committee.
As the Independent Director of Y-Mabs Therapeutics Inc, the total compensation of Johan Wedellsborg at Y-Mabs Therapeutics Inc is $228,025. There are 10 executives at Y-Mabs Therapeutics Inc getting paid more, with Claus Moller-San Pedro having the highest compensation of $967,497.
Johan Wedellsborg is 50, he's been the Independent Director of Y-Mabs Therapeutics Inc since 2015. There are 10 older and 7 younger executives at Y-Mabs Therapeutics Inc. The oldest executive at Y-Mabs Therapeutics Inc is Dr. Torben Lund-Hansen, 70, who is the Sr. VP & Chief Technical Officer.
Johan's mailing address filed with the SEC is C/O Y-MABS THERAPEUTICS, INC., 230 PARK AVENUE, SUITE 3350, NEW YORK, NY, 10169.
Over the last 6 years, insiders at Y-Mabs Therapeutics Inc have traded over $85,284,951 worth of Y-Mabs Therapeutics Inc stock and bought 1,819,126 units worth $23,554,756 . The most active insiders traders include James Healy, Thomas Gad oraz Johan Wedell Wedellsborg. On average, Y-Mabs Therapeutics Inc executives and independent directors trade stock every 14 days with the average trade being worth of $494,414. The most recent stock trade was executed by Torben Lund Hansen on 28 August 2024, trading 50,000 units of YMAB stock currently worth $219,000.
y-mabs is late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. the company has a broad and advanced product pipeline, including 2 pivotal-stage product candidates - naxitamab and omburtamab - which target tumors that express gd2 and b7-h3, respectively. our mission is to become the world leader in developing antibody-based cancer products that address clear unmet needs in pediatric oncology. with the right partnerships and collaboration, we envision expanding our capabilities to treat adults - changing the course of cancer and its outcome.
Y-Mabs Therapeutics Inc executives and other stock owners filed with the SEC include: